Compare BCG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | XLO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 39.4M |
| IPO Year | N/A | 2021 |
| Metric | BCG | XLO |
|---|---|---|
| Price | $2.00 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 5.3K | ★ 417.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.50 |
| 52 Week High | $3.44 | $1.18 |
| Indicator | BCG | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 49.01 |
| Support Level | $1.95 | $0.51 |
| Resistance Level | $2.10 | $0.61 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.87 | 60.94 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.